Search for: "Hyman, Phelps & McNamara, P.C." Results 121 - 140 of 175
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
ACI’s 10th Anniversary Paragraph IV Disputes Master Symposium
24 Jul 2024, 6:54 pm by Hyman Phelps McNamara
Other key program highlights this year include: Examining the Use of Clinical Trials as Prior Art: How to Thread the Needle on Protecting IP and Mandated Disclosures Patent Rights and Supply Chain Dynamics: Understanding How Developments in India May Affect Hatch-Waxman- Generic and Brand Perspectives Fireside Chat on Future of FDA Initiatives Affect Small Molecules: Regulatory Initiatives, and Agency Developments for Hatch Waxman Practitioners to Watch Hyman, Phelps &… [read post]
FDA Law Blog - https://www.thefdalawblog.com/
ACI’s 21st Annual Paragraph IV Disputes
12 Mar 2025, 7:52 pm by Hyman Phelps McNamara
Raimondo Exploring the On-Sale Bar and Applicability of Prior Art Orange Book Delisting Attempts Navigating ODP and Patent Family Dynamics Hyman, Phelps & McNamara, P.C. [read post]
FDA Law Blog - https://www.thefdalawblog.com/
ACI’s 23rd Advanced Summit on Life Sciences Patents
7 Apr 2025, 6:45 pm by Hyman Phelps McNamara
Hyman, Phelps & McNamara, P.C. [read post]
FDA Law Blog - https://www.thefdalawblog.com/
ACI’s 3rd Annual Forum on Advanced Therapeutics
3 Mar 2025, 1:45 am by Hyman Phelps McNamara
  Hyman, Phelps & McNamara, P.C. [read post]
FDA Law Blog - https://www.thefdalawblog.com/
ACI’s 42nd FDA Boot Camp – New York City Edition
24 Jan 2024, 2:48 am by Hyman Phelps McNamara
Karst (Director, Hyman, Phelps & McNamara, P.C.) and Stacy Cline Amin (Partner, Morrison & Foerster (Former Chief Counsel, U.S. [read post]
FDA Law Blog - https://www.thefdalawblog.com/
ACI’s 43rd FDA Boot Camp – New York City Edition
27 Feb 2025, 3:13 am by Hyman Phelps McNamara
This year’s conference co-chairs are Hyman, Phelps & McNamara, P.C. [read post]
FDA Law Blog - https://www.thefdalawblog.com/
ACI’s 4th Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA – October 8-24, 2024 (Virtual)
27 Aug 2024, 7:20 pm by Hyman Phelps McNamara
 Hyman, Phelps & McNamara, P.C. [read post]
FDA Law Blog - https://www.thefdalawblog.com/
Congratulations to HP&M’s first Principal Medical Device Regulation Expert, Adrienne Lenz
5 Jan 2022, 12:00 am by Hyman Phelps McNamara
Hyman, Phelps & McNamara, P.C. [read post]
FDA Law Blog - https://www.thefdalawblog.com/
FDASIA Enacted; HP&M Issues Detailed Summary and Analysis
11 Jul 2012, 1:25 pm by FDABlog HPM
Hyman, Phelps & McNamara, P.C. has prepared a detailed summary and analysis of FDASIA. [read post]
FDA Law Blog - http://www.fdalawblog.net/fda_law_blog_hyman_phelps/
HPM Director Dara Katcher Levy to Present Webinar on AMCP Format for Formulary Submissions v5.0
24 Jun 2024, 9:49 pm by Hyman Phelps McNamara
This afternoon Hyman, Phelps & McNamara, P.C. [read post]
FDA Law Blog - https://www.thefdalawblog.com/
“Thaw Out” with Pharma Thought Leaders at the 2024 Puerto Rico Pharmaceutical Summit: HPM Directors to Discuss Drug Approvals and Puerto Rico “Exportation” Best Practices
11 Jan 2024, 7:22 pm by Hyman Phelps McNamara
Two Hyman, Phelps & McNamara, P.C. [read post]
FDA Law Blog - https://www.thefdalawblog.com/
HP&M’s James Valentine & Ellis Unger @ DIA 2022: FDA Rare Disease Town Hall with CDER & CBER Center Directors, Optimizing Benefit-Risk Assessments, Reflecting on 10 Years of PFDD
2 Jun 2022, 8:02 pm by Hyman Phelps McNamara
Hyman, Phelps & McNamara, P.C. [read post]
FDA Law Blog - https://www.thefdalawblog.com/
HP&M Attorneys Receive Accolades: Top Lawyer Under 40 and WWL: Life Sciences 2023 Global Elite Thought Leader
27 Jun 2023, 2:29 am by Hyman Phelps McNamara
Valentine Named Top Lawyer Under 40; Only Food and Drug Lawyer Selected Hyman, Phelps & McNamara, P.C. [read post]
FDA Law Blog - https://www.thefdalawblog.com/
Even in “Unprecedented” Times, There is Precedent
17 Nov 2024, 6:48 pm by Kurt R. Karst
  Hyman, Phelps & McNamara, P.C. and the FDA Law Blog will keep our finger on the pulse of developments in the law and our readers informed of how those developments affect them. [read post]
FDA Law Blog - https://www.thefdalawblog.com/
FDLI Conference – Brands, Generics and Hatch-Waxman: New Challenges; Unabated Controversy
7 Jun 2011, 10:15 am by FDABlog HPM
Hyman, Phelps & McNamara, P.C. [read post]
FDA Law Blog - http://www.fdalawblog.net/fda_law_blog_hyman_phelps/
CMS Physician Sunshine Proposal Finally Sees Light of Day; HP&M Issues Summary Memorandum
22 Dec 2011, 5:48 pm by FDABlog HPM
  Hyman, Phelps & McNamara, P.C. has prepared a summary of the proposed rule, which is available here. [read post]
FDA Law Blog - http://www.fdalawblog.net/fda_law_blog_hyman_phelps/
Pharmacy Law and Licensing Highlights 2025
2 Feb 2025, 7:28 pm by Kurt R. Karst
Hyman, Phelps & McNamara, P.C’s licensing team will continue to track these issues and keep blog readers informed about state and federal licensing/registration issues that could affect them. [read post]
FDA Law Blog - https://www.thefdalawblog.com/
New IP resource for Pharma, Biotech and Chem – Compulsory licences, comparing national requirements
21 Mar 2011, 9:14 pm by Duncan
Karst, Hyman, Phelps & McNamara, P.C., United States Klaus Kupka, Taylor Wessing, Germany David C. [read post]
IP Thinktank - http://duncanbucknell.com/ipthinktank.blog
New IP resource for Pharma, Biotech and Chem – Confidential information protection and jurisdictional differences
18 May 2011, 9:45 pm by Duncan
Karst, Hyman, Phelps & McNamara, P.C., United States Klaus Kupka, Taylor Wessing, Germany David C. [read post]
IP Thinktank - http://duncanbucknell.com/ipthinktank.blog
New IP resource for Pharma, Biotech and Chem – Tie-in / tie-out clauses and competition
18 Apr 2011, 10:12 pm by Marie Louise
Karst, Hyman, Phelps & McNamara, P.C., United States Klaus Kupka, Taylor Wessing, Germany David C. [read post]
IP Thinktank - http://duncanbucknell.com/ipthinktank.blog